Nucleoside and nucleotide reverse transcriptase inhibitors

Lamivudine; Zidovudine

Approved 23 Jul 2009OralTablet

The FDA lists this product in 7 strengths and forms.

Official labelAsk Osler about it

Composition

Active ingredients: LAMIVUDINE 30MG; ZIDOVUDINE 60MG

Strengths and forms

The FDA lists each strength of a product separately; these pages share one label.

Official product information

Drugs@FDA lists the approved labels, letters and reviews for application NDA022296.

Open Drugs@FDA

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Brand name: Lamivudine; Zidovudine
Active substance: lamivudine
Drug class: Nucleoside and nucleotide reverse transcriptase inhibitors, Antivirals for treatment of HIV infections, combinations
Group: Antivirals
Route: Oral
Dosage form: Tablet
Applicant: Aurobindo Pharma LTD
Status: Tentative approval
FDA approval: 23 Jul 2009
Application: NDA022296-001
RxCUI: 214671